Arvinas (ARVN) Jefferies 2024 Global Healthcare Conference summary

Key conference insights

• Recent ASCO data, including postMONARCH and DESTINY, highlighted opportunities for improved regimens in HR-positive breast cancer, with significant PFS seen in combinations involving CDK4/6 inhibitors and degraders.

• Endocrine therapy remains the first-line standard, with chemotherapy reserved for more severe cases, reinforcing the importance of optimizing endocrine-based combinations.

• The VERITAC-2 study is designed for earlier-line patients, aiming for better outcomes than later-line settings, with anticipated ESR1 mutation rates of 40%-50%.

• Combination regimens with CDK4/6 inhibitors, especially with vepdegestrant, have shown promising double-digit median PFS, suggesting potential synergy and strong investigator interest.

• Ongoing and future studies will refine patient selection criteria and combination strategies, with regulatory discussions and trial designs evolving based on recent data.

Competitive landscape and regulatory strategy

• Oral degraders like vepdegestrant offer a safety and convenience advantage over injectable SERDs, with co-primary endpoints targeting both wild type and ESR1 mutant populations.

• Regulatory precedent suggests initial approval may focus on ESR1 mutants, but strong ITT results and a favorable safety profile could support a broader label.

• Combination studies with next-generation CDK4 inhibitors are prioritized, with data-driven decisions expected by late 2024 or early 2025 to guide first-line strategies.

• Drug-drug interaction studies indicate manageable safety profiles, with dose adjustments for palbociclib and minimal concerns for other CDK inhibitors.

• The partnership with Pfizer is robust, with both parties committed to maximizing the potential of vepdegestrant in various combinations and lines of therapy.

Forward-looking statements and trial plans

• The VERITAC-2 monotherapy study is expected to read out by year-end, with a second-line combination study planned for early 2025.

• Patient selection criteria, such as prior endocrine therapy duration, are being optimized to enrich for ESR1 mutations and exclude fast progressors.

• Additional combination arms, including with abemaciclib, ribociclib, and CDK7, are enrolling in ongoing studies, with potential for CDK6 combinations based on recent ASCO data.

• Safety and efficacy data from ongoing studies will inform dose selection and future trial designs, with a focus on achieving durable responses and broad regulatory approval.

• The strategic focus is on establishing vepdegestrant as a preferred endocrine therapy, leveraging both monotherapy and combination regimens.